



## CLAIMS

What is claimed is:

1. A compound, being a compound represented by Formula I-1 or Formula I-2; or being a tautomer, a stereoisomer, a hydrate, a solvate, or a salt of the compound represented by Formula I-1 or Formula I-2,



2. The compound according to claim 1, wherein the compound is one of the following compounds; or a tautomer, a stereoisomer, a hydrate, a solvate, or a salt of one of following compounds,



3. A pharmaceutical composition, comprising the compound according to claim 1 or 2 as an active ingredient.

4. Use of the compound according to claim 1 or 2 or the pharmaceutical composition according to claim 3 in manufacture of a medicament for treating or preventing ATX-related disease, wherein the ATX-related disease is selected from the group consisting of cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease,

cardiovascular disease, neurodegenerative diseases, dermatological disorder, abnormal angiogenesis-related disease, and combinations thereof.

5        5. The use according to claim 4, wherein the ATX-related disease is selected from the group consisting of interstitial lung disease, pulmonary fibrosis, liver fibrosis, renal fibrosis, and a combination thereof.

6. The use according to claim 4, wherein the ATX-related disease is idiopathic pulmonary fibrosis.

7. The use according to claim 4, wherein the ATX-related disease is selected from the group consisting of type II diabetes, nonalcoholic steatohepatitis, and a combination thereof.

10        8. The use according to claim 4, wherein the ATX-related disease is selected from the group consisting of neuropathic pain, inflammatory pain, and a combination thereof.

9. The use according to claim 4, wherein the ATX-related disease is osteoarthritis-related pain.

10. A drug combination, comprising:

15        the compound according to claim 1 or 2 or the pharmaceutical composition according to claim 3; and

an additional drug for treating or preventing ATX-related diseases, wherein the ATX-related disease is selected from the group consisting of cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, abnormal angiogenesis-related disease, and combinations thereof.

20        11. The compound according to claim 1 or 2, the pharmaceutical composition according to claim 3, or the drug combination according to claim 10 for use in therapy of ATX-related disease, wherein the compound, the pharmaceutical composition, or the drug combination is to be administered to a patient, and wherein the ATX-related disease is selected from the group consisting of cancer, metabolic disease, kidney disease, liver disease, fibrosis disease, interstitial lung disease, proliferation disease, inflammatory disease, pain, autoimmune disease, respiratory disease, cardiovascular disease, neurodegenerative diseases, dermatological disorder, abnormal angiogenesis-related disease, and combinations thereof.

30